Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV− oropharyngeal squamous cell carcinoma: A population-based study

Rate of locoregional recurrence among patients with oropharyngeal squamous cell carcinoma with known HPV status: a systematic review

“…The literature search generated 1652 articles, of which nine [14][15][16][17][18][19][20][21][22] were included (Figure 1). In total, the cohort consisted of 3668 patients (range: 121-1244 patients per study) treated for primary OPSCC, of which HPV status was known for 2974 patients.…”

“…Three studies [15,18,20] reported the median time to recurrence. One study found that the median time to recurrence was 1.1 years and 0.9 years for HPV-positive and -negative patients, respectively.…”

Reply to “Do not de‐escalate oncology care in oropharyngeal cancer routinely”

“…1,6,7 In a study by Fakhry et al median time to disease progression was also similar in HPV+ and in HPV− OPSCC, supporting close surveillance within the first 2 years in both groups. 1,6,7 In a study by Fakhry et al median time to disease progression was also similar in HPV+ and in HPV− OPSCC, supporting close surveillance within the first 2 years in both groups.…”

“…Although atypical sites of distant metastases have been reported in the literature, the most common sites are the lungs, liver, and bone, irrespective of HPV status. 1,6,7 In a study by Fakhry et al median time to disease progression was also similar in HPV+ and in HPV− OPSCC, supporting close surveillance within the first 2 years in both groups. 1 Whether early detection of distant metastasis in asymptomatic HPV+ OPSCC patients is beneficial in terms of life quality, psychosocial well-being, or survival is yet controversial.…”

Prediction of post-radiotherapy locoregional progression in HPV-associated oropharyngeal squamous cell carcinoma using machine-learning analysis of baseline PET/CT radiomics

“…Improved responsiveness to treatment and more indolent natural history of HPV-associated OPSCC may potentially render this prognostically favorable subtype amenable to treatment de-intensification with reduced treatment-related toxicity [ 6 , 7 ]. Nevertheless, treatment failure with locoregional disease progression (LRP) is a negative prognostic factor in HPV-associated OPSCC, often entailing salvage resection or irradiation which are commonly associated with increased morbidity and impaired functionality, and ultimately resulting in reduced overall survival [8] , [9] , [10] . Thus, there is a pressing need for novel biomarkers to identify patients amenable for safe treatment de-escalation and ultimately personalized clinical decision-making.…”